No biomarker
|
Juvenile Myelomonocytic Leukemia
|
No biomarker
|
Juvenile Myelomonocytic Leukemia
|
azacitidine Sensitive: A1 - Approval
FDA - 2 days (NewA1)
|
azacitidine Sensitive: A1 - Approval
FDA - 2 days - (New A1)
|
No biomarker
|
Astrocytoma
|
No biomarker
|
Astrocytoma
|
carmustine Sensitive: A1 - Approval
FDA - 6 days (NewA1)
|
carmustine Sensitive: A1 - Approval
FDA - 6 days - (New A1)
|
No biomarker
|
Ependymoma
|
No biomarker
|
Ependymoma
|
carmustine Sensitive: A1 - Approval
FDA - 6 days (NewA1)
|
carmustine Sensitive: A1 - Approval
FDA - 6 days - (New A1)
|
No biomarker
|
Medulloblastoma
|
No biomarker
|
Medulloblastoma
|
carmustine Sensitive: A1 - Approval
FDA - 6 days (NewA1)
|
carmustine Sensitive: A1 - Approval
FDA - 6 days - (New A1)
|
No biomarker
|
HL
|
No biomarker
|
HL
|
carmustine Sensitive: A1 - Approval
FDA - 6 days (NewA1)
|
carmustine Sensitive: A1 - Approval
FDA - 6 days - (New A1)
|
No biomarker
|
NHL
|
No biomarker
|
NHL
|
carmustine Sensitive: A1 - Approval
FDA - 6 days (NewA1)
|
carmustine Sensitive: A1 - Approval
FDA - 6 days - (New A1)
|
No biomarker
|
Glioma
|
No biomarker
|
Glioma
|
carmustine Sensitive: A1 - Approval
FDA - 6 days (NewA1)
|
carmustine Sensitive: A1 - Approval
FDA - 6 days - (New A1)
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
carmustine Sensitive: A1 - Approval
FDA - 6 days (NewA1)
|
carmustine Sensitive: A1 - Approval
FDA - 6 days - (New A1)
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
carmustine Sensitive: A1 - Approval
FDA - 6 days (NewA1)
|
carmustine Sensitive: A1 - Approval
FDA - 6 days - (New A1)
|
No biomarker
|
Thyroid Gland Carcinoma
|
No biomarker
|
Thyroid Gland Carcinoma
|
cabozantinib tablet Sensitive: A1 - Approval
Ipsen Press Release - 2 weeks (NewA1)
|
cabozantinib tablet Sensitive: A1 - Approval
Ipsen Press Release - 2 weeks - (New A1)
|
No biomarker
|
Follicular Lymphoma
|
No biomarker
|
Follicular Lymphoma
|
tisagenlecleucel-T Sensitive: A1 - Approval
Novartis Press Release - 2 weeks (NewA1)
|
tisagenlecleucel-T Sensitive: A1 - Approval
Novartis Press Release - 2 weeks - (New A1)
|
No biomarker
|
HCC
|
No biomarker
|
HCC
|
durvalumab + CP-675206 Sensitive: B - Late Trials
AstraZeneca Press Release - 3 weeks (NewB)
|
durvalumab + CP-675206 Sensitive: B - Late Trials
AstraZeneca Press Release - 3 weeks - (New B)
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
ONC-392 Sensitive: B - Late Trials
GlobeNewswire - 3 weeks (NewB)
|
ONC-392 Sensitive: B - Late Trials
GlobeNewswire - 3 weeks - (New B)
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
VB-111 Sensitive: B - Late Trials
VBL Therapeutics Press Release - 3 weeks (NewB)
|
VB-111 Sensitive: B - Late Trials
VBL Therapeutics Press Release - 3 weeks - (New B)
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
AUTO1 Sensitive: B - Late Trials
GlobeNewswire - 3 weeks (NewB)
|
AUTO1 Sensitive: B - Late Trials
GlobeNewswire - 3 weeks - (New B)
|
No biomarker
|
AML
|
No biomarker
|
AML
|
CFI-400945 Sensitive: B - Late Trials
Treadwell Therap Press Release - 3 weeks (NewB)
|
CFI-400945 Sensitive: B - Late Trials
Treadwell Therap Press Release - 3 weeks - (New B)
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
abemaciclib Sensitive: A2 - Guideline
ASCO.org - 4 weeks (NewA2)
|
abemaciclib Sensitive: A2 - Guideline
ASCO.org - 4 weeks - (New A2)
|
No biomarker
|
CRC
|
No biomarker
|
CRC
|
GCC19CART Sensitive: B - Late Trials
Innovative Cellular Therap Press Release - 4 weeks (NewB)
|
GCC19CART Sensitive: B - Late Trials
Innovative Cellular Therap Press Release - 4 weeks - (New B)
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
CMG901 Sensitive: B - Late Trials
Keymed Biosci Press Release - 4 weeks (NewB)
|
CMG901 Sensitive: B - Late Trials
Keymed Biosci Press Release - 4 weeks - (New B)
|
No biomarker
|
Gastric Cancer
|
No biomarker
|
Gastric Cancer
|
CMG901 Sensitive: B - Late Trials
Keymed Biosci Press Release - 4 weeks (NewB)
|
CMG901 Sensitive: B - Late Trials
Keymed Biosci Press Release - 4 weeks - (New B)
|
No biomarker
|
Marginal Zone Lymphoma
|
No biomarker
|
Marginal Zone Lymphoma
|
zanubrutinib Sensitive: A1 - Approval
|
zanubrutinib Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
pomalidomide + elotuzumab Sensitive: A1 - Approval
|
pomalidomide + elotuzumab Sensitive: A1 - Approval
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
lisocabtagene maraleucel Sensitive: A1 - Approval
|
lisocabtagene maraleucel Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
ramucirumab Sensitive: A1 - Approval
|
ramucirumab Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
durvalumab Sensitive: A1 - Approval
|
durvalumab Sensitive: A1 - Approval
|
No biomarker
|
RCC
|
No biomarker
|
RCC
|
nivolumab + cabozantinib tablet Sensitive: A1 - Approval
|
nivolumab + cabozantinib tablet Sensitive: A1 - Approval
|
No biomarker
|
Malignant Pleural Mesothelioma
|
No biomarker
|
Malignant Pleural Mesothelioma
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
No biomarker
|
Follicular Lymphoma
|
No biomarker
|
Follicular Lymphoma
|
axicabtagene ciloleucel Sensitive: A1 - Approval
|
axicabtagene ciloleucel Sensitive: A1 - Approval
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
axicabtagene ciloleucel Sensitive: A1 - Approval
|
axicabtagene ciloleucel Sensitive: A1 - Approval
|
No biomarker
|
Mediastinal B Cell Lymphoma
|
No biomarker
|
Mediastinal B Cell Lymphoma
|
axicabtagene ciloleucel Sensitive: A1 - Approval
|
axicabtagene ciloleucel Sensitive: A1 - Approval
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
No biomarker
|
Esophageal Cancer
|
No biomarker
|
Esophageal Cancer
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
No biomarker
|
Esophageal Squamous Cell Carcinoma
|
No biomarker
|
Esophageal Squamous Cell Carcinoma
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
niraparib Sensitive: A1 - Approval
|
niraparib Sensitive: A1 - Approval
|
No biomarker
|
Ovarian Cancer
|
No biomarker
|
Ovarian Cancer
|
niraparib Sensitive: A1 - Approval
|
niraparib Sensitive: A1 - Approval
|
No biomarker
|
Peritoneal Cancer
|
No biomarker
|
Peritoneal Cancer
|
niraparib Sensitive: A1 - Approval
|
niraparib Sensitive: A1 - Approval
|
No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
brexucabtagene autoleucel Sensitive: A1 - Approval
|
brexucabtagene autoleucel Sensitive: A1 - Approval
|
No biomarker
|
Esophageal Adenocarcinoma
|
No biomarker
|
Esophageal Adenocarcinoma
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
No biomarker
|
NHL
|
No biomarker
|
NHL
|
brentuximab vedotin Sensitive: A1 - Approval
|
brentuximab vedotin Sensitive: A1 - Approval
|
No biomarker
|
Gastric Cancer
|
No biomarker
|
Gastric Cancer
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
bevacizumab Sensitive: A1 - Approval
|
bevacizumab Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
nivolumab + ipilimumab Sensitive: A1 - Approval
|
No biomarker
|
Small Cell Lung Cancer
|
No biomarker
|
Small Cell Lung Cancer
|
durvalumab Sensitive: A1 - Approval
|
durvalumab Sensitive: A1 - Approval
|
No biomarker
|
SCCHN
|
No biomarker
|
SCCHN
|
cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval
|
cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval
|
No biomarker
|
Gastric Adenocarcinoma
|
No biomarker
|
Gastric Adenocarcinoma
|
cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval
|
cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval
|
cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
cisplatin + pemetrexed Sensitive: A1 - Approval
|
cisplatin + pemetrexed Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive: A1 - Approval
|
docetaxel + doxorubicin hydrochloride + cyclophosphamide Sensitive: A1 - Approval
|
No biomarker
|
BCC
|
No biomarker
|
BCC
|
fluorouracil topical Sensitive: A1 - Approval
|
fluorouracil topical Sensitive: A1 - Approval
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
cisplatin Sensitive: A1 - Approval
|
cisplatin Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
carfilzomib Sensitive: A1 - Approval
|
carfilzomib Sensitive: A1 - Approval
|
No biomarker
|
Thyroid Gland Medullary Carcinoma
|
No biomarker
|
Thyroid Gland Medullary Carcinoma
|
cabozantinib capsule Sensitive: A1 - Approval
|
cabozantinib capsule Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
No biomarker
|
Lung Non-Squamous Non-Small Cell Cancer
|
atezolizumab Sensitive: A1 - Approval
|
atezolizumab Sensitive: A1 - Approval
|
No biomarker
|
Small Cell Lung Cancer
|
No biomarker
|
Small Cell Lung Cancer
|
atezolizumab Sensitive: A1 - Approval
|
atezolizumab Sensitive: A1 - Approval
|
No biomarker
|
AML
|
No biomarker
|
AML
|
glasdegib Sensitive: A1 - Approval
|
glasdegib Sensitive: A1 - Approval
|
No biomarker
|
HCC
|
No biomarker
|
HCC
|
pembrolizumab Sensitive: A1 - Approval
|
pembrolizumab Sensitive: A1 - Approval
|
No biomarker
|
HCC
|
No biomarker
|
HCC
|
bevacizumab + atezolizumab Sensitive: A1 - Approval
|
bevacizumab + atezolizumab Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
bortezomib + panobinostat Sensitive: A1 - Approval
|
bortezomib + panobinostat Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
bortezomib + pegylated liposomal doxorubicin Sensitive: A1 - Approval
|
bortezomib + pegylated liposomal doxorubicin Sensitive: A1 - Approval
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
rituximab Sensitive: A1 - Approval
|
rituximab Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
tislelizumab Sensitive: A1 - Approval
|
tislelizumab Sensitive: A1 - Approval
|
No biomarker
|
Lymphoma
|
No biomarker
|
Lymphoma
|
axicabtagene ciloleucel Resistant: A1 - Approval
|
axicabtagene ciloleucel Resistant: A1 - Approval
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
No biomarker
|
Diffuse Large B Cell Lymphoma
|
tisagenlecleucel-T Sensitive: A1 - Approval
|
tisagenlecleucel-T Sensitive: A1 - Approval
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
No biomarker
|
B Acute Lymphoblastic Leukemia
|
tisagenlecleucel-T Sensitive: A1 - Approval
|
tisagenlecleucel-T Sensitive: A1 - Approval
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
No biomarker
|
Childhood B Acute Lymphoblastic Leukemia
|
tisagenlecleucel-T Sensitive: A1 - Approval
|
tisagenlecleucel-T Sensitive: A1 - Approval
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
apalutamide Sensitive: A1 - Approval
|
apalutamide Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
rituximab + ibrutinib Sensitive: A1 - Approval
|
rituximab + ibrutinib Sensitive: A1 - Approval
|
No biomarker
|
SCCHN
|
No biomarker
|
SCCHN
|
nivolumab Sensitive: A1 - Approval
|
nivolumab Sensitive: A1 - Approval
|
No biomarker
|
AML
|
No biomarker
|
AML
|
azacitidine oral Sensitive: A1 - Approval
|
azacitidine oral Sensitive: A1 - Approval
|
No biomarker
|
NSCLC
|
No biomarker
|
NSCLC
|
DP Sensitive: A1 - Approval
|
DP Sensitive: A1 - Approval
|
No biomarker
|
Gastric Cancer
|
No biomarker
|
Gastric Cancer
|
TPF Sensitive: A1 - Approval
|
TPF Sensitive: A1 - Approval
|
No biomarker
|
Urothelial Cancer
|
No biomarker
|
Urothelial Cancer
|
avelumab Sensitive: A1 - Approval
|
avelumab Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
SVd Sensitive: A1 - Approval
|
SVd Sensitive: A1 - Approval
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
No biomarker
|
Gastroesophageal Junction Adenocarcinoma
|
TPF Sensitive: A1 - Approval
|
TPF Sensitive: A1 - Approval
|
No biomarker
|
SCCHN
|
No biomarker
|
SCCHN
|
TPF Sensitive: A1 - Approval
|
TPF Sensitive: A1 - Approval
|
No biomarker
|
AML
|
No biomarker
|
AML
|
cytarabine/daunorubicin liposomal formulation Sensitive: A1 - Approval
|
cytarabine / daunorubicin liposomal formulation Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
ciltacabtagene autoleucel Sensitive: A1 - Approval
|
ciltacabtagene autoleucel Sensitive: A1 - Approval
|
No biomarker
|
Soft Tissue Sarcoma
|
No biomarker
|
Soft Tissue Sarcoma
|
olaratumab Sensitive: A1 - Approval
|
olaratumab Sensitive: A1 - Approval
|
No biomarker
|
Colon Cancer
|
No biomarker
|
Colon Cancer
|
capecitabine Sensitive: A1 - Approval
|
capecitabine Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
venetoclax + obinutuzumab Sensitive: A1 - Approval
|
venetoclax + obinutuzumab Sensitive: A1 - Approval
|
No biomarker
|
Rectal Cancer
|
No biomarker
|
Rectal Cancer
|
FOLFIRI Sensitive: A1 - Approval
|
FOLFIRI Sensitive: A1 - Approval
|
No biomarker
|
Breast Cancer
|
No biomarker
|
Breast Cancer
|
TAC Sensitive: A1 - Approval
|
TAC Sensitive: A1 - Approval
|
No biomarker
|
Urothelial Cancer
|
No biomarker
|
Urothelial Cancer
|
sacituzumab govitecan-hziy Sensitive: A1 - Approval
|
sacituzumab govitecan-hziy Sensitive: A1 - Approval
|
No biomarker
|
Colon Cancer
|
No biomarker
|
Colon Cancer
|
5-fluorouracil + irinotecan Sensitive: A1 - Approval
|
5-fluorouracil + irinotecan Sensitive: A1 - Approval
|
No biomarker
|
Multiple Myeloma
|
No biomarker
|
Multiple Myeloma
|
pomalidomide Sensitive: A1 - Approval
|
pomalidomide Sensitive: A1 - Approval
|
No biomarker
|
Burkitt Lymphoma
|
No biomarker
|
Burkitt Lymphoma
|
cyclophosphamide Sensitive: A1 - Approval
|
cyclophosphamide Sensitive: A1 - Approval
|
No biomarker
|
Burkitt Lymphoma
|
No biomarker
|
Burkitt Lymphoma
|
rituximab Sensitive: A1 - Approval
|
rituximab Sensitive: A1 - Approval
|
No biomarker
|
Adrenal Cortex Carcinoma
|
No biomarker
|
Adrenal Cortex Carcinoma
|
mitotane Sensitive: A1 - Approval
|
mitotane Sensitive: A1 - Approval
|
No biomarker
|
Neuroendocrine Tumor
|
No biomarker
|
Neuroendocrine Tumor
|
surufatinib Sensitive: A1 - Approval
|
surufatinib Sensitive: A1 - Approval
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
bevacizumab Sensitive: A1 - Approval
|
bevacizumab Sensitive: A1 - Approval
|
No biomarker
|
Peritoneal Cancer
|
No biomarker
|
Peritoneal Cancer
|
bevacizumab Sensitive: A1 - Approval
|
bevacizumab Sensitive: A1 - Approval
|
No biomarker
|
Peritoneal Cancer
|
No biomarker
|
Peritoneal Cancer
|
rucaparib Sensitive: A1 - Approval
|
rucaparib Sensitive: A1 - Approval
|
No biomarker
|
Peritoneal Cancer
|
No biomarker
|
Peritoneal Cancer
|
olaparib Sensitive: A1 - Approval
|
olaparib Sensitive: A1 - Approval
|
No biomarker
|
CRC
|
No biomarker
|
CRC
|
bevacizumab Sensitive: A1 - Approval
|
bevacizumab Sensitive: A1 - Approval
|
No biomarker
|
Peritoneal Cancer
|
No biomarker
|
Peritoneal Cancer
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Mvasi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Peritoneal Cancer
|
No biomarker
|
Peritoneal Cancer
|
Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Aybintio (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
Onbevzi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Onbevzi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Peritoneal Cancer
|
No biomarker
|
Peritoneal Cancer
|
Onbevzi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Onbevzi (bevacizumab biosimilar) Sensitive: A1 - Approval
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
rucaparib Sensitive: A1 - Approval
|
rucaparib Sensitive: A1 - Approval
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
olaparib Sensitive: A1 - Approval
|
olaparib Sensitive: A1 - Approval
|
No biomarker
|
Peritoneal Cancer
|
No biomarker
|
Peritoneal Cancer
|
carboplatin + micellar paclitaxel Sensitive: A1 - Approval
|
carboplatin + micellar paclitaxel Sensitive: A1 - Approval
|
No biomarker
|
Fallopian Tube Cancer
|
No biomarker
|
Fallopian Tube Cancer
|
carboplatin + micellar paclitaxel Sensitive: A1 - Approval
|
carboplatin + micellar paclitaxel Sensitive: A1 - Approval
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
histrelin acetate Sensitive: A1 - Approval
|
histrelin acetate Sensitive: A1 - Approval
|
No biomarker
|
Prostate Cancer
|
No biomarker
|
Prostate Cancer
|
cabazitaxel Sensitive: A1 - Approval
|
cabazitaxel Sensitive: A1 - Approval
|
No biomarker
|
Retinoblastoma
|
No biomarker
|
Retinoblastoma
|
cyclophosphamide Sensitive: A1 - Approval
|
cyclophosphamide Sensitive: A1 - Approval
|
No biomarker
|
Mantle Cell Lymphoma
|
No biomarker
|
Mantle Cell Lymphoma
|
orelabrutinib Sensitive: A1 - Approval
|
orelabrutinib Sensitive: A1 - Approval
|
No biomarker
|
Small Lymphocytic Lymphoma
|
No biomarker
|
Small Lymphocytic Lymphoma
|
orelabrutinib Sensitive: A1 - Approval
|
orelabrutinib Sensitive: A1 - Approval
|
No biomarker
|
CLL
|
No biomarker
|
CLL
|
orelabrutinib Sensitive: A1 - Approval
|
orelabrutinib Sensitive: A1 - Approval
|
No biomarker
|
GBM
|
No biomarker
|
GBM
|
Byvasda (bevacizumab biosimilar) Sensitive: A1 - Approval
|
Byvasda (bevacizumab biosimilar) Sensitive: A1 - Approval
|